Airnexis Therapeutics
AirNexus | AirNexis Therapeutics Launches with $200M Series A
Palo Alto, United States · Founded 2026 · $200.0M raised
- Headquarters
- Palo Alto, California
- Employees
- 11–50
- Founded
- 2026
- Business Model
- B2B
- Website
- airnexis.com
- Total Funding
- $200.0M
- Last Round
- $200.0M Series AJan 2026
- Rounds
- 1
About
AirNexis Therapeutics is a clinical-stage biotech company developing novel therapeutic drugs for the treatment of COPD and pulmonary diseases. Its lead asset AN01 is a dual PDE3/4 inhibitor advancing into Phase 2 clinical trials, targeting bronchodilation and anti-inflammatory effects in COPD patients. The company launched in January 2026 with a $200M Series A led by Frazier Life Sciences.
Summary
Airnexis Therapeutics is a Biotech company based in Palo Alto, United States, founded in 2026. It has raised $200.0M in total across 1 round, most recently a $200.0M Series A round in Jan 2026. Investors include Frazier Life Sciences, OrbiMed and SR One.
Tech & App Stack
4 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Jan 2026
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/airnexis-therapeutics"><img src="https://indexed.vc/api/badge/company/airnexis-therapeutics" alt="Airnexis Therapeutics on Indexed.vc" width="260" height="76" /></a>